2seventy bio Stock Price, News & Analysis (NASDAQ:TSVT) $1.94 +0.11 (+6.01%) (As of 12/1/2023 08:55 PM ET) Add Compare Share Share Today's Range$1.68▼$1.9550-Day Range$1.57▼$4.4952-Week Range$1.54▼$16.17Volume775,200 shsAverage Volume1.17 million shsMarket Capitalization$98.22 millionP/E RatioN/ADividend YieldN/APrice Target$11.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media 2seventy bio MarketRank™ Stock AnalysisAnalyst RatingHold2.14 Rating ScoreUpside/Downside475.6% Upside$11.17 Price TargetShort InterestBearish26.17% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.99) to ($1.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.24 out of 5 starsMedical Sector369th out of 957 stocksPharmaceutical Preparations Industry158th out of 436 stocks 4.1 Analyst's Opinion Consensus Rating2seventy bio has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 1 buy rating, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.17, 2seventy bio has a forecasted upside of 475.6% from its current price of $1.94.Amount of Analyst Coverage2seventy bio has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted26.17% of the float of 2seventy bio has been sold short.Short Interest Ratio / Days to Cover2seventy bio has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in 2seventy bio has recently increased by 8.84%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend Yield2seventy bio does not currently pay a dividend.Dividend Growth2seventy bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TSVT. Previous Next 2.8 News and Social Media Coverage News Sentiment2seventy bio has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for 2seventy bio this week, compared to 2 articles on an average week.Search Interest8 people have searched for TSVT on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 2seventy bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.60% of the stock of 2seventy bio is held by insiders.Percentage Held by Institutions98.49% of the stock of 2seventy bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for 2seventy bio are expected to grow in the coming year, from ($3.99) to ($1.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 2seventy bio is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 2seventy bio is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio2seventy bio has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About 2seventy bio Stock (NASDAQ:TSVT)2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and chimeric antigen receptor-T cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.Read More TSVT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TSVT Stock News HeadlinesNovember 30, 2023 | markets.businessinsider.comBiotech Stocks Facing FDA Decision In December 2023November 24, 2023 | americanbankingnews.comWedbush Research Analysts Raise Earnings Estimates for 2seventy bio, Inc. (NASDAQ:TSVT)December 4, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 23, 2023 | markets.businessinsider.comHold Rating for 2seventy Bio Amid Regulatory Risks and Potential Upsides: An Analysis on KarMMa-3 Study Outcomes and Stock PerformanceNovember 21, 2023 | msn.comWedbush Downgrades 2seventy bio (TSVT)November 20, 2023 | msn.comBristol Myers Squibb slumps as FDA convenes advisory panel for drug applicationNovember 20, 2023 | bizjournals.com2seventy slides on latest roadblock for cancer drugNovember 20, 2023 | reuters.comUS FDA delays decision on Bristol Myers-2seventy bio cancer therapyDecember 4, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 17, 2023 | markets.businessinsider.comDaina Graybosch Maintains ‘Hold’ Rating for 2seventy Bio Amid Revenue Decline and Market ChallengesNovember 14, 2023 | finance.yahoo.com2seventy bio Inc (TSVT) Reports Q3 Financial Results Amid Competitive Market DynamicsNovember 14, 2023 | benzinga.com2seventy bio: Q3 Earnings InsightsNovember 13, 2023 | markets.businessinsider.com2seventy bio earnings: here's what Wall Street expectsNovember 13, 2023 | benzinga.comPreview: 2seventy bio's EarningsNovember 10, 2023 | finance.yahoo.com2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023October 30, 2023 | msn.comLeerink Partners Downgrades 2seventy bio (TSVT)October 30, 2023 | finance.yahoo.com2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Should You Buy?October 13, 2023 | msn.comCitigroup Initiates Coverage of 2seventy bio (TSVT) with Buy RecommendationSeptember 18, 2023 | bizjournals.com2seventy bio reveals how many in Cambridge will be cut in mass layoffSeptember 14, 2023 | reuters.com2seventy bio to lay off 40% of workforceSeptember 13, 2023 | msn.comGoldman Sachs Downgrades 2seventy bio (TSVT)September 13, 2023 | markets.businessinsider.com2seventy Bio's Cost Cuts Prudent But Analyst Says It Induces Lower Confidence In Lead ProductSeptember 13, 2023 | msn.comGuggenheim Downgrades 2seventy bio (TSVT)September 12, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for 2seventy bioSeptember 12, 2023 | reuters.com2seventy bio CEO to step down, plans job cutsSeptember 12, 2023 | markets.businessinsider.com2seventy Bio Announces Restructuring, To Reduce 176 RolesSeptember 12, 2023 | finance.yahoo.com2seventy bio and JW Therapeutics Announce Intent To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune TherapiesSee More Headlines Receive TSVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 2seventy bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today12/03/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TSVT CUSIPN/A CIK1860782 Webwww.2seventybio.com Phone339-499-9300FaxN/AEmployees425Year FoundedN/APrice Target and Rating Average Stock Price Target$11.17 High Stock Price Target$26.00 Low Stock Price Target$4.00 Potential Upside/Downside+475.6%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-254,150,000.00 Net Margins-126.06% Pretax Margin-126.06% Return on Equity-47.12% Return on Assets-23.78% Debt Debt-to-Equity RatioN/A Current Ratio4.08 Quick Ratio4.08 Sales & Book Value Annual Sales$91.50 million Price / Sales1.07 Cash FlowN/A Price / Cash FlowN/A Book Value$6.05 per share Price / Book0.32Miscellaneous Outstanding Shares50,630,000Free Float49,309,000Market Cap$98.22 million OptionableNot Optionable Beta1.14 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Nick Leschly (Age 50)President, CEO & Director Comp: $1.81MDr. Philip D. Gregory D. Phil. (Age 52)DPHIL, Chief Scientific Officer Comp: $1.01MMr. William D. Baird III (Age 51)M.B.A., Principal Financial Officer, Principal Accounting Officer & Chief Operating Officer Comp: $810.83kMs. Susan Abu-Absi Ph.D.Chief Technology OfficerMs. Teresa L. Jurgensen J.D.Senior VP, General Counsel & Corporate SecretaryMs. Kerri JensenHead of People & CultureMs. Jenn SnyderSenior Vice President of Corporate AffairsDr. Steven Bernstein M.D.Chief Medical OfficerMichael CertoVP & Head of Genome EditingMore ExecutivesKey CompetitorsCarisma TherapeuticsNASDAQ:CARMShattuck LabsNASDAQ:STTKMilestone PharmaceuticalsNASDAQ:MISTEton PharmaceuticalsNASDAQ:ETONApollomicsNASDAQ:APLMView All CompetitorsInsiders & InstitutionsWellington Management Group LLPBought 114,549 shares on 12/1/2023Ownership: 5.914%American Century Companies Inc.Bought 10,825 shares on 11/30/2023Ownership: 0.067%Graham Capital Management L.P.Bought 50,166 shares on 11/22/2023Ownership: 0.150%Jacobs Levy Equity Management Inc.Bought 258,265 shares on 11/17/2023Ownership: 1.540%Diversified Trust CoBought 10,379 shares on 11/17/2023Ownership: 0.020%View All Insider TransactionsView All Institutional Transactions TSVT Stock Analysis - Frequently Asked Questions Should I buy or sell 2seventy bio stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 2seventy bio in the last year. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" TSVT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TSVT, but not buy additional shares or sell existing shares. View TSVT analyst ratings or view top-rated stocks. What is 2seventy bio's stock price target for 2024? 7 analysts have issued 12 month price objectives for 2seventy bio's shares. Their TSVT share price targets range from $4.00 to $26.00. On average, they anticipate the company's share price to reach $11.17 in the next year. This suggests a possible upside of 475.6% from the stock's current price. View analysts price targets for TSVT or view top-rated stocks among Wall Street analysts. How have TSVT shares performed in 2023? 2seventy bio's stock was trading at $9.37 at the beginning of the year. Since then, TSVT stock has decreased by 79.3% and is now trading at $1.94. View the best growth stocks for 2023 here. When is 2seventy bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our TSVT earnings forecast. What ETFs hold 2seventy bio's stock? ETFs with the largest weight of 2seventy bio (NASDAQ:TSVT) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Horizon Kinetics Medical ETF (MEDX), Goldman Sachs Future Health Care Equity ETF (GDOC).Global X Genomics & Biotechnology ETF (GNOM), Who are 2seventy bio's major shareholders? 2seventy bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Kynam Capital Management LP (11.80%), Newtyn Management LLC (6.10%), Wellington Management Group LLP (5.91%), CHI Advisors LLC (1.99%), Jacobs Levy Equity Management Inc. (1.54%) and Charles Schwab Investment Management Inc. (1.08%). Insiders that own company stock include Kynam Capital Management, Lp, Nick Leschly, Nicola Heffron, Philip D Gregory and William D Baird III. View institutional ownership trends. How do I buy shares of 2seventy bio? Shares of TSVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:TSVT) was last updated on 12/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 2seventy bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.